Citigroup Maintains Buy on Biohaven, Raises Price Target to $17

Benzinga Newsdesk www.benzinga.com Positive 75.0%

Neg 0% Neu 0% Pos 75%

Citigroup analyst Samantha Semenkow maintains Biohaven (NYSE:BHVN) with a Buy and raises the price target from $14 to $17.